Optimization of immunologic testing

Dried blood spots can be a reliable test to detect SARS-CoV-2 antibodies

In a study now published in Microbiology Spectrum, a team of Vancouver investigators, led by Dr. Agatha Jassem of the British Columbia Center for Disease Control (BCCDC) and partially funded by the CITF, demonstrated that dried blood spot (DBS) testing should be considered reliable in detecting SARS-CoV-2 seropositivity acquired from both natural infection and vaccination.

2022-04-19T10:29:52-04:00March 18, 2022|Optimization of immunologic testing|

A Canadian platform to study the antibody response to SARS-CoV-2 infection and vaccination

In a paper now published in Clinical and Translational Immunology, a team of Canadian researchers partly funded by the CITF and led by Drs. Anne-Claude Gingras from Toronto’s Lunenfeld-Tanenbaum Research Institute, Marc-André Langlois from the University of Ottawa, and Yves Durocher from the National Research Council of Canada, has developed a set of standardized, high-throughput serological assays to detect antibodies against SARS-CoV-2.

2022-04-19T10:29:43-04:00October 29, 2021|Optimization of immunologic testing|

‘Made-in-Canada’ assays perform well to measure seroprevalence

Despite the many assays available to test for SARS-CoV-2 antibodies, a gold standard has not yet been established. In an article now published in PLOS ONE, CITF Testing Working Group members Dr. Anne-Claude Gingras from the University of Toronto, and Dr. Steven Drews from Canadian Blood Services, evaluate multiple testing platforms and the concordance between test results in this CITF-funded study. P

2022-04-19T10:29:38-04:00October 5, 2021|Optimization of immunologic testing|
Go to Top